After 6 years with Xolair; a 3-year withdrawal follow-up

Research output: Contribution to journalArticle

Standard

After 6 years with Xolair; a 3-year withdrawal follow-up. / Nopp, A.; Johansson, S. G. O.; Adedoyin, J.; Ankerst, Jaro; Palmqvist, M.; Oman, H.

In: Allergy, Vol. 65, No. 1, 2010, p. 56-60.

Research output: Contribution to journalArticle

Harvard

Nopp, A, Johansson, SGO, Adedoyin, J, Ankerst, J, Palmqvist, M & Oman, H 2010, 'After 6 years with Xolair; a 3-year withdrawal follow-up', Allergy, vol. 65, no. 1, pp. 56-60. https://doi.org/10.1111/j.1398-9995.2009.02144.x

APA

Nopp, A., Johansson, S. G. O., Adedoyin, J., Ankerst, J., Palmqvist, M., & Oman, H. (2010). After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy, 65(1), 56-60. https://doi.org/10.1111/j.1398-9995.2009.02144.x

CBE

MLA

Vancouver

Author

Nopp, A. ; Johansson, S. G. O. ; Adedoyin, J. ; Ankerst, Jaro ; Palmqvist, M. ; Oman, H. / After 6 years with Xolair; a 3-year withdrawal follow-up. In: Allergy. 2010 ; Vol. 65, No. 1. pp. 56-60.

RIS

TY - JOUR

T1 - After 6 years with Xolair; a 3-year withdrawal follow-up

AU - Nopp, A.

AU - Johansson, S. G. O.

AU - Adedoyin, J.

AU - Ankerst, Jaro

AU - Palmqvist, M.

AU - Oman, H.

PY - 2010

Y1 - 2010

N2 - P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.

AB - P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.

KW - omalizumab

KW - CD-sens

KW - IgE antibody

U2 - 10.1111/j.1398-9995.2009.02144.x

DO - 10.1111/j.1398-9995.2009.02144.x

M3 - Article

C2 - 19796193

VL - 65

SP - 56

EP - 60

JO - Allergy

JF - Allergy

SN - 1398-9995

IS - 1

ER -